Commentary

Video

Unveiling the Latest in HER2+ Breast Cancer and Beyond With Drs Sara Hurvitz and Neil Iyengar

Author(s):

Chandler Park, MD, MSc, FACP,Sara A. Hurvitz, MD, FACP

Sara Hurvitz, MD, of Fred Hutch Cancer Center, and Neil Iyengar, MD, of Memorial Sloan Kettering Cancer Center, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in breast cancer presented during the 2024 San Antonio Breast Cancer Symposium.

Sara Hurvitz, MD, of Fred Hutch Cancer Center, and Neil Iyengar, MD, of Memorial Sloan Kettering Cancer Center, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in breast cancer presented during the 2024 San Antonio Breast Cancer Symposium.

Related Videos
Eytan M. Stein, MD
Azka Ali, MD, medical oncologist, Cleveland Clinic Taussig Cancer Institute
Rena Callahan, MD, and Chandler Park, MD, FACP
Hope S. Rugo, MD, FASCO, Winterhof Family Endowed Professor in Breast Cancer, professor, Department of Medicine (Hematology/Oncology), director, Breast Oncology and Clinical Trials Education; medical director, Cancer Infusion Services; the University of California San Francisco Helen Diller Family Comprehensive Cancer Center
Virginia Kaklamani, MD, DSc, professor, medicine, Division of Hematology-Medical Oncology, The University of Texas (UT) Health Science Center San Antonio; leader, breast cancer program, Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center
Aditya Bardia, MD, MPH, FASCO, professor, Department of Medicine, Division of Hematology/Oncology, director, Translational Research Integration, UCLA Health Jonsson Comprehensive Cancer Center
John M. Burke, MD
Eunice S. Wang, MD
Rachel E. Rau, MD
Timothy S. Fenske, MD, MS
Related Content
Breast Cancer | stock.adobe.com
December 12th 2024

Tamoxifen Reduces Ipsilateral Breast Recurrence in Good-Risk Ductal CIS

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Ribociclib and Endocrine Therapy in Breast Cancer | Image Credit: © Axel Kock – stock.adobe.com
December 12th 2024

Certain Breast Cancer Subtypes May Derive a Greater Benefit With Ribociclib Combo vs Chemo

MedNews Week
September 4th 2024

Park and Graff Explore the Evolving Role of CDK4/6 Inhibitors in Metastatic Breast Cancer

ASH Annual Meeting | Image Credit: © Tatiana Shepeleva – stock.adobe.com
December 12th 2024

Iopofosine I 131 Is Efficacious, Tolerable in Heavily Pretreated R/R Waldenström Macroglobulinemia

James J. Harding, MD, associate attending physician at Memorial Sloan Kettering Cancer Center
December 12th 2024

Zanidatamab Proves Efficacious in Pretreated Biliary Tract Cancer With Potential to Move to the Frontline